aap Implantate has announced a solid start to 2017 with Q1 trauma sales increasing by 30% to €2.9m and total sales up 23% to €3.1m, slightly ahead of company guidance of €1.8m to €2.8m. This is significant as 2017 is the first year following the company’s transformation into a pure trauma player and suggests that traction is starting to develop following initiatives to drive sales in the established markets. Increasing market penetration in Europe and the US remains
18 May 2017
Solid start to 2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid start to 2017
aap Implantate AG (AAQ1:ETR) | 0 0 5.5% | Mkt Cap: 50.5m
- Published:
18 May 2017 -
Author:
Dr Linda Pomeroy -
Pages:
2
aap Implantate has announced a solid start to 2017 with Q1 trauma sales increasing by 30% to €2.9m and total sales up 23% to €3.1m, slightly ahead of company guidance of €1.8m to €2.8m. This is significant as 2017 is the first year following the company’s transformation into a pure trauma player and suggests that traction is starting to develop following initiatives to drive sales in the established markets. Increasing market penetration in Europe and the US remains